- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/4196 - 1,2,4-Triazoles
Patent holdings for IPC class A61K 31/4196
Total number of patents in this class: 2972
10-year publication summary
|
192
|
163
|
206
|
209
|
203
|
179
|
161
|
153
|
182
|
195
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Synta Pharmaceuticals Corp. | 171 |
77 |
| Axsome Therapeutics, Inc. | 280 |
70 |
| F. Hoffmann-La Roche AG | 7934 |
49 |
| Novartis AG | 10626 |
48 |
| Karyopharm Therapeutics Inc. | 142 |
38 |
| Merck Sharp & Dohme LLC | 3732 |
32 |
| Hoffmann-La Roche Inc. | 3534 |
30 |
| Genentech, Inc. | 4008 |
30 |
| Boehringer Ingelheim International GmbH | 4637 |
29 |
| Bayer Pharma AG | 1049 |
29 |
| Ardea Biosciences, Inc. | 71 |
27 |
| Gilead Sciences, Inc. | 2085 |
27 |
| Bristol-myers Squibb Company | 4824 |
24 |
| Pfizer Inc. | 3404 |
23 |
| The Regents of the University of California | 20268 |
21 |
| Eli Lilly and Company | 3911 |
20 |
| BASF SE | 21072 |
18 |
| Bayer AG | 3388 |
18 |
| Board of Regents, The University of Texas System | 5927 |
18 |
| Havah Therapeutics Pty Ltd | 19 |
18 |
| Other owners | 2326 |